Actym Therapeutics Announces Lead Candidate for Clinical Development, Presentation at SITC

BERKELEY, Calif.: BERKELEY, Calif., Nov. 12, 2021 /PRNewswire/ -- Actym Therapeutics today announced that ACTM-838 has been selected as a lead clinical development candidate for the treatment of solid tumors. ACTM-838 is based on the company's immunotherapy platform called STACT (S. Typhimurium-Attenuated Cancer Therapy), which delivers multiplexed immuno-modulatory payloads directly...

Click to view original post